The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Crossover from one aromatase inhibitor (AI) to another in the Exemestane and Letrozole Pharmacogenetics (ELPh) trial.
 
Kunal C. Kadakia
No Relationships to Disclose
 
Kelley M Kidwell
No Relationships to Disclose
 
Nicholas J. Seewald
No Relationships to Disclose
 
Claire Frances Snyder
Stock and Other Ownership Interests - Express Scripts; Immunomedics; Merck; Oncolytics
Consulting or Advisory Role - Pfizer; Walgreens (Inst)
Research Funding - Genentech (Inst); WellPoint (Inst)
 
David A. Flockhart
Research Funding - Novartis; Pfizer
 
Janet S Carpenter
No Relationships to Disclose
 
Julie L. Otte
Honoraria - On Q Health
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Honoraria - Lilly
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Lilly (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
 
Anna Maria Storniolo
Honoraria - Pfizer
Research Funding - Novartis; Pfizer
 
Vered Stearns
Research Funding - Abbvie; Celgene; MedImmune; Merck; Novartis; Pfizer; Puma Biotechnology
 
Norah Lynn Henry
Research Funding - BioMarin; Celldex; Sanofi
Travel, Accommodations, Expenses - Celldex